ADC Therapeutics Ltd (ADCT)

In the past six months, ADC Therapeutics' stock price has seen a significant increase of 51.32%. As of February 6, 2026, the stock price was $4.01, with a 52-week range of $1.05 to $4.80. Recent events impacting the stock include a share price decrease on February 6, 2026, grants of options to new employees on February 2, 2026, a reiterated "sell" rating by Weiss Ratings on January 21, 2026, preliminary revenue and cash estimates reported on January 8, 2026, an upgrade to a "Buy" rating by Zacks on December 29, 2025 and November 18, 2025, an update on the LOTIS-7 clinical trial on December 3, 2025, an upgrade to a "hold" rating by Wall Street Zen on November 15, 2025, reaffirmed "buy" rating by Guggenheim on November 12, 2025, quarterly earnings reported on November 10, 2025, and a cut in the target price by HC Wainwright on October 16, 2025.

Information regarding specific demand seasonality for ADC Therapeutics SA's products and services is not explicitly detailed. Demand for its products like ZYNLONTA would primarily be driven by the incidence and prevalence of the specific cancers it treats and would likely be consistent throughout the year. The company is actively working to expand the usage of ZYNLONTA into earlier lines of therapy and in combinations, which could increase its market penetration and overall demand. The success of ongoing clinical trials and the development of new pipeline candidates will also be key drivers of future demand.

ADC Therapeutics SA is a commercial-stage biotechnology company focused on improving the lives of cancer patients through its proprietary next-generation, targeted antibody drug conjugates (ADCs). The company operates within the Health Technology sector, specifically in the Pharmaceuticals and Biotechnology industries. ADC Therapeutics utilizes its proprietary pyrrolobenzodiazepine (PBD)-based ADC technology to develop treatments for both hematologic malignancies and solid tumors. Its major products and pipeline candidates include ZYNLONTA® (loncastuximab tesirine-lpyl), an FDA-approved CD19-directed ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Cami (camidanlumab tesirine), an ADC targeting CD25, currently in a pivotal Phase 2 clinical trial for relapsed or refractory Hodgkin lymphoma; ADCT-601, an AXL-targeting ADC; ADCT-602, in a Phase 1/2 clinical trial for the treatment of acute lymphoblastic leukemia; ADCT-212, ADCT-701, ADCT-901, second-generation PBD-based ADCs targeting prostate-specific membrane antigen (PSMA); and a preclinical pipeline that includes investigational ADCs targeting Claudin-6, NaPi2b, and ASCT2.

ADC Therapeutics SA is headquartered in Lausanne (Biopôle), Switzerland, with its corporate office in Epalinges, Vaud. The company also has operations in London, the San Francisco Bay Area, and New Jersey, USA. It serves customers in the United States, Switzerland, and the United Kingdom. ZYNLONTA has received accelerated approval in the U.S., conditional approval from the European Commission, and conditional approval from the China National Medical Products Administration, and the company is seeking to expand it into other international markets.

ADC Therapeutics aims to be a leading antibody drug conjugate company that transforms the lives of cancer patients. The company emphasizes its commitment to making a positive impact on patients' lives with innovative ADC products and has over a decade of experience in the field. ADC Therapeutics released its inaugural Environmental, Social and Governance (ESG) report in February 2022, detailing its focus on patient care and sustainable innovation, highlighting its commitment to being good corporate citizens. The company also focuses on patient access, safety, and support, and emphasizes human capital and a diverse workforce.

ADC Therapeutics SA has 166 institutional owners and shareholders holding a total of 72,404,514 shares, representing 32.76% of the common stock, valued at $162.75M. Hedge funds collectively own 30% of the shares. Major institutional owners include Redmile Group, LLC, Point72 Asset Management, L.P., Prosight Management, LP, Orbimed Advisors Llc, BlackRock, Inc., Morgan Stanley, Nantahala Capital Management, LLC, IWM - iShares Russell 2000 ETF, Goldman Sachs Group Inc, TCG Crossover Management, LLC, Redco II Master Fund, L.P., Hpwh Th AG, and Brookfield Corporation. The company's CEO, Ameet Mallik, directly holds 1.4% of the total shares outstanding.